Download Sample
Add to CartGlobal Psoriatic Arthritis Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Type of Molecule;
Biologics and Small Molecules.By Drug Class;
Non-steroidal Anti-inflammatory Drugs (NSAIDS), Non-biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), and Others.By Route Of Administration;
Oral, Parenteral, and Topical.By Dosage Form;
Solid, Liquid and Semi-Solid.By Distribuation Channel;
Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.By Geography;
North America, Europe, Asia Pacific, Middle East & Africa and Latin America - Report Timeline (2021 - 2031).Psoriatic Arthritis Market Overview
Psoriatic Arthritis Market (USD Million)
Psoriatic Arthritis Market was valued at USD 13,160.22 million in the year 2024. The size of this market is expected to increase to USD 21,691.68 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 7.4%.
Global Psoriatic Arthritis Market Growth, Share, Size, Trends and Forecast
*Market size in USD million
CAGR 7.4 %
| Study Period | 2025 - 2031 |
|---|---|
| Base Year | 2024 |
| CAGR (%) | 7.4 % |
| Market Size (2024) | USD 13,160.22 Million |
| Market Size (2031) | USD 21,691.68 Million |
| Market Concentration | Medium |
| Report Pages | 335 |
Major Players
- AbbVie Inc.
- Amgen Inc.
- Bristol Myers Squibb Company
- Johnson & Johnson Services, Inc.
- Novartis AG
- Pfizer Inc.
- UCB S.A.
- Eli Lilly and Company
- Celgene Corporation
- AstraZeneca PLC
Market Concentration
Consolidated - Market dominated by 1 - 5 major players
Global Psoriatic Arthritis Market
Fragmented - Highly competitive market without dominant players
The Psoriatic Arthritis Market is steadily advancing due to the rising burden of autoimmune diseases. Psoriatic arthritis affects close to 30% of individuals who suffer from psoriasis, and the demand for targeted treatment is growing. Increased awareness of this condition is driving early intervention and improved disease management strategies.
Adoption of Biologics Driving Therapeutic Shifts
The growing preference for biologic therapies is reshaping treatment frameworks. Currently, more than 55% of therapeutic protocols rely on biologics due to their effectiveness in reducing joint inflammation and slowing disease progression. These treatments are increasingly favored for managing advanced stages of psoriatic arthritis.
Role of Technology in Enhancing Treatment
Digital technologies are gaining prominence in the psoriatic arthritis care ecosystem. With nearly 25% of patients using remote monitoring systems, the focus is shifting toward personalized and data-driven care. These advancements support continuous disease tracking and better adherence to treatment plans.
Strong Research Backing and Clinical Support
Continued clinical research and evidence-based treatment guidelines are enhancing therapeutic approaches. Psoriatic arthritis now accounts for nearly 35% of clinical trial activity in the autoimmune space. These efforts are expanding access to novel therapies and reinforcing the importance of precision medicine.
Psoriatic Arthritis Market Recent Developments
-
In 2023, the advent of Janus kinase (JAK) inhibitors and IL-17 inhibitors significantly impacted the market, providing enhanced therapeutic options. Market leaders like Eli Lilly leveraged this trend by introducing advanced formulations aimed at improving patient quality of life.
-
In 2022, Amgen's advancements in biosimilars for psoriatic arthritis allowed for cost-effective alternatives to conventional therapies, thereby increasing accessibility and creating growth opportunities, especially in emerging markets.
Psoriatic Arthritis Market Segment Analysis
In this report, the Psoriatic Arthritis Market has been segmented by Type of Molecule, Drug Class, Route Of Administration, Dosage Form, Distribuation Channel and Geography.
Psoriatic Arthritis Market, Segmentation by Type of Molecule
The Psoriatic Arthritis Market has been segmented by Type of Molecule into Biologics and Small molecules.
Biologics
Biologics are a dominant class of drugs in the treatment of psoriatic arthritis, accounting for approximately 70% of the market share. These include medications like TNF inhibitors, interleukin inhibitors, and JAK inhibitors. Biologics work by targeting specific proteins involved in the immune response, helping reduce inflammation and prevent joint damage in patients.
Small Molecules
Small molecules, such as methotrexate and leflunomide, represent a smaller segment of the psoriatic arthritis market, contributing around 30% to the total market share. These drugs work by modifying the immune system's response and are often used in the early stages of treatment or as adjuncts to biologics for patients with moderate to severe disease.
Psoriatic Arthritis Market, Segmentation by Drug Class
The Psoriatic Arthritis Market has been segmented by Drug Class into Non-steroidal Anti-inflammatory Drugs (NSAIDS), Non-biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), and Others.
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
NSAIDs, such as ibuprofen and naproxen, are commonly used in the treatment of psoriatic arthritis to reduce pain, inflammation, and stiffness. These drugs account for approximately 25% of the market share, offering a first-line treatment option for managing mild to moderate symptoms of the disease.
Non-biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)
Non-biologic DMARDs, including methotrexate and leflunomide, are used to slow disease progression by modifying the immune response. This drug class holds a market share of around 35%, particularly for patients with moderate to severe psoriatic arthritis who do not yet require biologics.
Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)
Biologic DMARDs, such as TNF inhibitors and interleukin inhibitors, represent a rapidly growing segment, accounting for approximately 30% of the market. These drugs target specific components of the immune system and are highly effective in treating moderate to severe psoriatic arthritis that has not responded to traditional treatments.
Others
The "Others" category includes medications such as steroids and JAK inhibitors. This segment makes up around 10% of the market, providing alternative treatment options for patients with severe disease or those who experience inadequate response to standard therapies.
Psoriatic Arthritis Market, Segmentation by Route Of Administration
The Psoriatic Arthritis Market has been segmented by Route Of Administration into Oral, Parenteral, and Topical.
Oral
Oral administration is one of the most common routes for psoriatic arthritis treatments, particularly for non-biologic DMARDs and NSAIDs. Drugs like methotrexate, leflunomide, and ibuprofen are often administered orally and make up approximately 40% of the market. Oral treatments are preferred for their convenience and ease of use, especially for long-term management of mild to moderate cases.
Parenteral
Parenteral administration, which includes injections and infusions, is typically used for biologic treatments such as TNF inhibitors and interleukin inhibitors. This route accounts for around 45% of the market. Parenteral drugs are effective in treating moderate to severe psoriatic arthritis, especially for patients who do not respond well to oral treatments.
Topical
Topical treatments, such as corticosteroids and topical NSAIDs, are primarily used for localized symptom relief in milder cases of psoriatic arthritis. While they represent a smaller segment of the market, contributing around 15%, they offer a targeted approach with minimal systemic side effects, making them an attractive option for managing joint pain and inflammation in early-stage disease.
Psoriatic Arthritis Market, Segmentation by Dosage Form
The Psoriatic Arthritis Market has been segmented by Dosage Form into Solid, Liquid and Semi-solid.
Solid
Solid dosage forms, such as tablets and capsules, are widely used in the treatment of psoriatic arthritis. These include oral medications like methotrexate, leflunomide, and NSAIDs. Solid forms account for approximately 50% of the market, offering convenience and ease of use for patients who require long-term management of their condition.
Liquid
Liquid dosage forms are often used for biologics and systemic treatments. These include injections and infusions for drugs like TNF inhibitors and interleukin inhibitors. The liquid form represents around 35% of the market, providing a fast-acting and effective delivery method for patients with moderate to severe psoriatic arthritis who need more intensive treatment.
Semi-solid
Semi-solid dosage forms, such as creams, gels, and ointments, are commonly used for localized treatment of psoriatic arthritis symptoms. These topical treatments, including corticosteroids and NSAIDs, make up around 15% of the market. Semi-solids are ideal for managing mild to moderate cases, providing targeted relief for joint pain and inflammation.
Psoriatic Arthritis Market, Segmentation by Distribuation Channel
The Psoriatic Arthritis Market has been segmented by Distribuation Channel into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.
Hospital Pharmacies
Hospital pharmacies play a significant role in the distribution of psoriatic arthritis treatments, especially for biologics and other prescription medications. This distribution channel accounts for approximately 50% of the market. Hospital pharmacies are often preferred for their ability to handle complex medications, such as TNF inhibitors and interleukin inhibitors, that require professional administration or monitoring.
Retail Pharmacies
Retail pharmacies are the most common point of access for patients seeking over-the-counter treatments and non-prescription medications, such as NSAIDs and topical corticosteroids. This channel contributes around 35% of the market, offering convenience and accessibility for patients managing mild to moderate psoriatic arthritis.
Online Pharmacies
Online pharmacies have seen rapid growth in the psoriatic arthritis market, especially as patients seek the convenience of home delivery for both prescription and over-the-counter treatments. Online pharmacies represent about 15% of the market, offering a wide range of products and enabling patients to access treatments like methotrexate and biologics with ease.
Psoriatic Arthritis Market, Segmentation by Geography
In this report, the Psoriatic Arthritis Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East & Africa and Latin America.
Regions and Countries Analyzed in this Report
Psoriatic Arthritis Market Share (%), by Geographical Region
North America
North America is the largest market for psoriatic arthritis treatments, accounting for approximately 40% of the global market share. The U.S. leads this region, driven by advanced healthcare systems, high awareness of psoriatic arthritis, and widespread adoption of biologic therapies such as TNF inhibitors and interleukin inhibitors.
Europe
Europe holds the second-largest share of the psoriatic arthritis market, contributing around 30% of the global market. Countries like Germany, the UK, and France are key players, with strong healthcare infrastructures and increasing adoption of both biologic and non-biologic treatments. The region also benefits from a high prevalence of psoriatic arthritis and robust treatment availability.
Asia Pacific
The Asia Pacific region is experiencing rapid growth in the psoriatic arthritis market, with a share of about 15%. Rising healthcare access, greater awareness of the condition, and increasing adoption of biologic treatments are driving this market, particularly in countries like China, Japan, and India.
Middle East and Africa
The Middle East and Africa region represents approximately 10% of the psoriatic arthritis market. The market is expanding due to improving healthcare infrastructure, greater awareness of chronic autoimmune diseases, and increased accessibility to biologic and systemic treatments in countries like Saudi Arabia and South Africa.
Latin America
Latin America contributes around 5% to the psoriatic arthritis treatment market. The market is gradually growing, particularly in Brazil and Mexico, driven by better healthcare access, increased awareness of psoriatic arthritis, and a growing demand for biologic therapies.
Psoriatic Arthritis Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Psoriatic Arthritis Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Comprehensive Market Impact Matrix
This matrix outlines how core market forces—Drivers, Restraints, and Opportunities—affect key business dimensions including Growth, Competition, Customer Behavior, Regulation, and Innovation.
| Market Forces ↓ / Impact Areas → | Market Growth Rate | Competitive Landscape | Customer Behavior | Regulatory Influence | Innovation Potential |
|---|---|---|---|---|---|
| Drivers | High impact (e.g., tech adoption, rising demand) | Encourages new entrants and fosters expansion | Increases usage and enhances demand elasticity | Often aligns with progressive policy trends | Fuels R&D initiatives and product development |
| Restraints | Slows growth (e.g., high costs, supply chain issues) | Raises entry barriers and may drive market consolidation | Deters consumption due to friction or low awareness | Introduces compliance hurdles and regulatory risks | Limits innovation appetite and risk tolerance |
| Opportunities | Unlocks new segments or untapped geographies | Creates white space for innovation and M&A | Opens new use cases and shifts consumer preferences | Policy shifts may offer strategic advantages | Sparks disruptive innovation and strategic alliances |
Drivers, Restraints and Opportunity Analysis
Drivers
- Increasing Prevalence of Psoriasis
- Rising Awareness and Diagnosis of Psoriatic Arthritis
-
Advancements in Treatment Modalities - The psoriatic arthritis market is witnessing steady expansion, largely driven by continuous advancements in treatment modalities that are redefining clinical approaches and enhancing patient care. The emergence of innovative biologics and small molecule therapies has significantly improved the ability to manage both the inflammatory and dermatological aspects of the disease. These modern therapies offer more precise targeting of disease pathways, enabling better symptom control with fewer side effects compared to traditional treatments.
Breakthroughs such as TNF-alpha inhibitors, IL-17 and IL-23 blockers, and JAK inhibitors have transformed the therapeutic landscape for moderate to severe psoriatic arthritis. These drugs not only reduce pain and inflammation but also help to slow or prevent joint damage, thereby preserving mobility and improving long-term quality of life. Their effectiveness in treating both joint and skin symptoms simultaneously has made them a cornerstone in modern treatment regimens, especially for patients unresponsive to conventional therapies.
The rise of personalized medicine is also playing a critical role in driving market growth. Treatment strategies are increasingly tailored based on individual factors such as disease severity, genetic markers, lifestyle, and existing comorbidities. This patient-specific approach is improving treatment outcomes and minimizing adverse reactions, leading to better adherence and sustained disease management. As the understanding of psoriatic arthritis at the molecular level deepens, the ability to deliver customized therapy continues to improve.
The global drug development pipeline remains active with numerous candidates undergoing clinical trials. Ongoing research is aimed at developing therapies with enhanced efficacy, faster onset of action, and greater safety profiles. These efforts are expected to further expand treatment choices and improve access to next-generation solutions. As a result, advancements in therapeutic innovation remain a central force in shaping the evolution of the psoriatic arthritis market and supporting its long-term growth trajectory.
Restraints
- High Cost of Biologic Therapies
- Side Effects Associated with Treatments
-
Stringent Regulatory Requirements - Significant challenge in the psoriatic arthritis market. Due to the dual nature of the disease—affecting both joints and skin—treatments must demonstrate broad-spectrum efficacy. Regulatory bodies such as the FDA and EMA demand extensive clinical evidence to validate safety and effectiveness, particularly for biologics and targeted therapies. This results in long development timelines and increased investment needs, ultimately delaying the availability of new treatments for patients.
The path to approval typically involves multi-phase clinical trials that must accommodate diverse patient responses and disease manifestations. Therapies are required to meet rigorous benchmarks across various parameters, such as inflammation reduction, mobility improvement, and skin clearance. Moreover, chronic use of these drugs necessitates long-term safety data, further complicating the regulatory process. Smaller pharmaceutical firms often struggle with these demands due to limited financial and operational resources, slowing innovation in the market.
The evolving nature of global regulations adds further complexity. Frequent updates in clinical guidelines and shifting expectations for trial design require companies to constantly adapt their development strategies. Regulators are placing increasing emphasis on long-term risk assessments and patient-reported outcomes, which can require restructured studies and additional time for compliance. These continuous modifications not only delay product launches but also inflate development costs and increase the risk of project abandonment.
Approval challenges are even greater in regions with non-unified regulatory systems. Variations in documentation, safety standards, and trial expectations make global market access difficult and time-consuming. This leads to delayed treatment availability in many emerging markets, limiting the reach of new therapies. Until international regulatory frameworks become more harmonized and innovation-friendly, stringent approval demands will remain a key restraint on the expansion and accessibility of advanced treatments for psoriatic arthritis.
Opportunities
- Expansion of Biosimilars Market
- Personalized Medicine Approaches
-
Integration of Digital Health Technologies - The growing adoption of digital health technologies is opening promising opportunities in the psoriatic arthritis market. Given the chronic and variable nature of the condition, these tools are enhancing disease management by enabling long-term tracking, personalized interventions, and improved patient engagement. From mobile health apps to wearable devices and telemedicine platforms, digital innovations are transforming how patients and healthcare providers monitor symptoms, adjust treatments, and maintain consistent communication.
One of the key advantages of digital integration is the ability to collect real-time data on patient health. Wearables and mobile apps can track metrics such as joint stiffness, pain intensity, skin lesion severity, and overall mobility. This continuous data flow gives physicians a more comprehensive understanding of disease activity between visits, allowing them to respond quickly to changes and refine treatment plans based on objective trends, thereby improving clinical outcomes and reducing avoidable healthcare utilization.
Telemedicine is also playing a significant role, particularly for patients in remote areas or those with limited access to specialists. Virtual consultations help ensure timely follow-ups and greater convenience, which is critical in maintaining treatment adherence for chronic conditions. These digital visits facilitate regular monitoring without the need for in-person appointments, improving both the efficiency and accessibility of care while promoting stronger patient-provider relationships.
Advancements in artificial intelligence and data analytics further strengthen the potential of digital health tools. By processing large volumes of patient-specific data, these technologies support personalized treatment by predicting disease flares, evaluating drug efficacy, and recommending targeted therapy modifications. As global healthcare systems continue to invest in digital infrastructure, the integration of such solutions is expected to enhance disease control, expand market reach, and elevate the standard of care for psoriatic arthritis patients worldwide.
Psoriatic Arthritis Market Competitive Landscape Analysis
Key players in Psoriatic Arthritis Market include:
- AbbVie Inc.
- Amgen Inc.
- Bristol Myers Squibb Company
- Johnson & Johnson Services, Inc.
- Novartis AG
- Pfizer Inc.
- UCB S.A.
- Eli Lilly and Company
- Celgene Corporation
- AstraZeneca PLC
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Market Share Analysis
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Type of Molecule
- Market Snapshot, By Drug Class
- Market Snapshot, By Route Of Administration
- Market Snapshot, By Dosage Form
- Market Snapshot, By Distribuation Channel
- Market Snapshot, By Region
- Psoriatic Arthritis Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Increasing Prevalence of Psoriasis
- Rising Awareness and Diagnosis of Psoriatic Arthritis
- Advancements in Treatment Modalities
- Restraints
- High Cost of Biologic Therapies
- Side Effects Associated with Treatments
- Stringent Regulatory Requirements
- Opportunities
- Expansion of Biosimilars Market
- Personalized Medicine Approaches
- Integration of Digital Health Technologies
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Psoriatic Arthritis Market, By Type of Molecule, 2021 - 2031 (USD Million)
- Biologics
- Small molecules
- Psoriatic Arthritis Market, By Drug Class, 2021 - 2031 (USD Million)
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
- Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)
- Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)
- Others
- Psoriatic Arthritis Market, By Route Of Administration, 2021 - 2031 (USD Million)
- Oral
- Parenteral
- Topical
- Psoriatic Arthritis Market, By Dosage Form, 2021 - 2031 (USD Million)
- Solid
- Liquid
- Semi-solid
- Psoriatic Arthritis Market, By Distribuation Channel, 2021 - 2031 (USD Million)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Psoriatic Arthritis Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Psoriatic Arthritis Market, By Type of Molecule, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- AbbVie Inc.
- Amgen Inc.
- Bristol Myers Squibb Company
- Johnson & Johnson Services, Inc.
- Novartis AG
- Pfizer Inc.
- UCB S.A.
- Eli Lilly and Company
- Celgene Corporation
- AstraZeneca PLC
- Company Profiles
- Analyst Views
- Future Outlook of the Market